Moonlake Immunotherapeutics (MLTX) Hedge Fund & Institutional Holdings (Q2 2026)

MLTX ranks #3341 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MLTX is a disclosed holding of David Shaw (D. E. Shaw & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

MLTX is a top-conviction position for Bvf Inc/il — at 8.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

MLTX is up 1.2% today, and institutions have been net buyers of $259.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MLTX reported a net loss of $227.3M in its latest fiscal year.

• Not yet profitable — net loss of $227.3M in the latest fiscal year
• Net income declined year over year, from -$118.9M to -$227.3M
• Operating cash flow was negative, using $196.0M in cash
• Current ratio of 9.27x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.39x equity — within a conventional range